

## Focus on new entrants

Next generation or technology startups and large tech companies continue to threaten the status quo.

- More than **250 startups** are focused on gene-based therapeutic solutions.
- **Six** of the top **ten** tech giants are diversifying into health care and life sciences.
- They are developing both diagnostics and therapeutics, and using their deep understanding of the consumer to enhance and simplify the patient experience.

Also witnessing regulatory disruption as a result of tech companies



## Next gen therapies

Adoptive cell transfer

Monoclonal antibody

Gene therapy

Immunotherapies

Cancer vaccines



Lack of manufacturing capacity is expected to continue to present a significant challenge for next-generation therapies

**Deloitte.**

[www.deloitte.com/lifesciencesoutlook](http://www.deloitte.com/lifesciencesoutlook)

### About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. Please see [www.deloitte.com/about](http://www.deloitte.com/about) for a more detailed description of DTTL and its member firms. Deloitte provides audit, consulting, financial advisory, risk management, tax and related services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries and territories, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte's more than 200,000 professionals are committed to becoming the standard of excellence.

### Disclaimer

This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively the "Deloitte Network") is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

### About Life Sciences and Health Care at Deloitte Touche Tohmatsu Limited

The Deloitte Touche Tohmatsu Limited's life sciences and health care (LSHC) industry group is composed of more than 12,000 professionals in more than 90 countries. These member firm professionals understand the complexity of today's life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today's environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information about the DTTL LSHC industry group, email [dtllshc@deloitte.com](mailto:dtllshc@deloitte.com) or access [www.deloitte.com/lifesciencesoutlook](http://www.deloitte.com/lifesciencesoutlook).  
©2019. For more information, contact Deloitte Touche Tohmatsu Limited.